Notizie AIOM – anno XV n. 620
Phase I, Dose-Escalation, 2-Part Trial of Poly(ADP-Ribose) Polymerase Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Talazoparib inhibits poly(ADP-ribose) polymerase (PARP) catalytic activity, trapping PARP1 on damaged DNA and causing cell death in BRCA1/2-mutated cells. We evaluated talazoparib therapy in this 2-part, phase I, first-in-human trial. Antitumor activity, maximum tolerated ...Leggi tutto
ASCO Endorses ACS Head and Neck Cancer Survivorship Care Guideline
March 8, 2017 - As reported in the Journal of Clinical Oncology by Larissa Nekhlyudov, MD, MPH, of Brigham & Women’s Hospital, Harvard Medical School, and colleagues, ASCO has endorsed the 2016 American Cancer Society (ACS) guideline on head and neck cancer survivorship ...Leggi tutto
FDA Lifts Clinical Hold on Vadastuximab Talirine Trials in AML
March 6, 2017 - The FDA has lifted its clinical hold on several phase I trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML), according to Seattle Genetics, the manufacturer of the antibody-drug conjugate. In late December 2016, the FDA enacted the ...Leggi tutto
FDA Review Continues for Pembrolizumab in MSI-H Cancer
March 10, 2017 - A supplemental biologics license application (sBLA) for pembrolizumab for previously treated patients with advanced microsatellite instability-high (MSI-H) cancer remains under review by the FDA, according to a statement from Merck, the manufacturer of the ...Leggi tutto
Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
To explore the impact of primary debulking surgery (PDS) to minimal but gross residual disease (RD) in women with bulky stage IIIC ovarian, fallopian tube, or primary peritoneal cancer. We retrospectively reviewed all patients with the aforementioned diagnosis who underwent ...Leggi tutto
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Patients with metastatic urothelial carcinoma have a dismal prognosis and few treatment options after first-line chemotherapy. Responses to second-line treatment are uncommon. We assessed nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for safety ...Leggi tutto
Patterns of computed tomography surveillance in survivors of colorectal cancer at Veterans Health Administration facilities
Annual computed tomography (CT) scans are a component of the current standard of care for the posttreatment surveillance of survivors of colorectal cancer (CRC) after curative-intent resection. The authors conducted a retrospective study with the primary aim of assessing ...Leggi tutto
Precision medicine needs randomized clinical trials
The advent of precision medicine has prompted profound changes in clinical cancer research, and the rising numbers of new therapeutic agents pose challenges in terms of the most appropriate trial designs and effects on the drug-approval process. In the past 5 years, some ...Leggi tutto